USPTO serial 99199767
PERSIST
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- FARRAG, SHERIF G
- Law office
- TMO LAW OFFICE 116
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PERSIST?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Philadelphia, PA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Candice Kwok
Candice Kwok Squire Patton Boggs (US) LLP555 California Street, Suite 550San Francisco, CA 94104United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, single-administration gene therapy products for the treatment and long-term management of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious disease, oncology, or neurological disorders; gene therapy products for medical purposes, namely, pharmaceutical preparations for the treatment of metabolic, autoimmune, cardiovascular, infectious disease, oncology, or neurological disorders; therapeutic preparations comprising viral vectors for gene delivery; biopharmaceuticals for modifying genetic expression to treat chronic and inherited conditions, namely, metabolic, autoimmune, cardiovascular, infectious disease, oncology, or neurological disorders; injectable gene therapy products for use in treating metabolic, autoimmune, cardiovascular, or neurological disorders; biologics in the nature of pharmaceutical preparations for the treatment of chronic diseases, metabolic, autoimmune, cardiovascular, infectious disease, oncology, or neurological disorders; biological preparations for the prevention or treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious disease, oncology, or neurological disorders; injectable pharmaceutical preparations for treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious disease, oncology, or neurological disorders; long-duration medicines for treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious disease, oncology, or neurological disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 16, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 16, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 16, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 16, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 26, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Dec 26, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 26, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 26, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 26, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 26, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 26, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 20, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 20, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 9, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 23, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 23, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 23, 2025 | NWAP | NEW APPLICATION ENTERED | — |